Ngm Biopharmaceuticals, Inc.

Hugo Matern

Wenyan Shen

Darrin Anthony Lindhout

Raj Haldankar

Taruna Arora

Yu Chen

Betty Chan Li

Kalyani Mondal

Yan Wang

Jie Tang

Zhonghao Liu

Geoffrey Horner

The present disclosure provides binding proteins, such as antibodies or binding fragments thereof, that bind beta klotho, including human beta klotho, and methods of their use such as in producing an antibody or binding fragment thereof. The present disclosure also provides vectors and cells comprising polynucleotides encoding antibodies or binding fragments thereof that bind beta klotho, including human beta klotho.

Polynucleotides encoding human beta klotho antibodies or binding fragments thereof and methods of use thereof

The present disclosure provides binding proteins, such as antibodies, that bind to a GDNF Family Receptor Alpha Like (GFRAL) protein, including human GFRAL protein, and methods of their use.

Binding proteins and methods of use thereof

A complex comprising a GDF15 polypeptide is described. Methods of treating individuals with a metabolism disorder, such as, glucose metabolism disorder and/or a body weight disorder, and compositions associated therewith, are provided.

Compositions and methods of use for treating metabolic disorders

The present disclosure provides binding proteins, such as antibodies, that bind glucagon receptors, including a human glucagon receptor, and methods of their use.

Methods of reducing or lowering blood glucose levels in a human subject by administering an antibody that specifically binds human glucagon receptor

The present disclosure provides binding proteins, such as antibodies, and binding fragments thereof, that bind beta klotho, including human beta klotho, and exemplary specific sequences of their complementarity determining regions, variable regions, heavy chains, and light chains. The present disclosure also provides method of making the antibody or fragment thereof and methods of their use, including, in activating beta-klotho/FGF receptor complex, inducing FGF19-like and/or FGF21-like signaling, improving glucose and lipid metabolism, and treatment of nonalcoholic steatohepatitis.

Anti-human beta klotho antibody or binding fragment thereof and methods of their use

The present disclosure provides binding proteins, such as antibodies and binding fragments thereof, that bind beta klotho, including human beta klotho, and methods of their use, including in the treatment of nonalcoholic steatohepatitis. The present disclosure also provides exemplary specific sequences of complementarity determining regions, variable regions, heavy chains, and light chains of the antibodies and/or binding fragments thereof.

Methods of treating nonalcoholic steatohepatitis comprising administering an anti-human beta klotho antibody or binding fragment thereof

Antibodies which bind human glucagon receptor

The present disclosure provides binding proteins, such as antibodies, that bind beta klotho, including human beta klotho, and methods of their use.

Beta klotho-binding proteins

Beta klotho-binding proteins and methods of use thereof

Methods of treating individuals with a glucose metabolism disorder and/or a body weight disorder, and compositions associated therewith, are provided.

Growing community of inventors

San Mateo, CA, United States of America

Hugo Matern